Doc’s note: Recently, my inbox has been flooded with e-mails from readers asking me about CBD and marijuana. And with this week’s Cannabis Investing Event, I want to share an essay you might have missed
And if you want to learn about the investment opportunities in the cannabis industry, don’t miss this week’s Cannabis Investing Event.
This Wednesday, March 27th at 8 p.m. Eastern time, our newest Senior Analyst will be joined by one of the most successful cannabis experts in the country to explain exactly what’s happening in the cannabis market right now – and how you can profit.
Reefer madness hit the 2019 Oscars.
No, we’re not talking about the psychedelic and fear-mongering 1930s propaganda film designed to terrorize parents about the “dangers” of marijuana.
This past weekend, Hollywood’s biggest stars received gift bags at the annual awards ceremony containing the latest fad – products infused with the key compounds of cannabis. That includes cannabidiol (CBD) skin care products, as well as chocolates infused with tetrahydrocannabinol, (THC). (Maybe the actors wanted a less painful way to get through the hours of pomp and circumstance.)
But across the country, shops selling CBD-laced products (like lattes and cookies) have been met with a crackdown from federal regulators. Earlier this month, the U.S. Department of Health and Human Services confiscated thousands of dollars worth of CBD-infused goods from different shops.
Maybe you’ve seen an increase in products in your area, too. Here in Baltimore, we have CBD advertisements in local vape shops and a bakery that makes CBD-infused donuts.
The boom in the cannabis industry hasn’t gone unnoticed. We’ve gotten a ton of emails from our readers asking us about CBD and marijuana. It’s a lot to cover, but we wanted to share some of the basics today.
Two of the main active components in cannabis are THC and CBD. Both of these compounds act the same way… they mimic a transmitter in our bodies called an endocannabinoid. These transmitters – and the plant-based versions – bind to receptors in our bodies.
These receptors control things like mood, appetite, memory, and pain. There are two types – CB1 and CB2.
CB1 receptors are in our brains, organs, and nervous systems. CB2 receptors are in our immune systems.
THC is often called the stronger “psychotropic” compound. That’s because it binds strongly to CB1 receptors in the brain. It causes the high you experience from marijuana and THC-laced products.
But CBD binds weakly to these transmitters. It also interferes with THC, so if you ingest or inhale both, you won’t get as much of a psychoactive effect as with THC alone. In other words, CBD won’t get you high, but since it dulls pain receptors and alleviates anxiety, it still acts on your brain.
CBD oil primarily comes from the hemp plant, not from marijuana. But both hemp and marijuana belong to the Cannabis family of plants.
Hemp has very little THC. So it’s a better plant option if you’re just after the CBD oil. Hemp is also protected on the federal level under the Farm Bill, which was finalized last year. It’s the first time hemp has had a separate exemption from other cannabis plants.
Hemp used to be legal until WWII, when certain states began to outlaw its growth due to a growing fear of marijuana dangers. Then in the 1970s, President Nixon made it illegal on the federal level, as he banned all types of the cannabis plant. We finally saw a turning point for hemp just this past year.
The sale and possession of any hemp-derived products (including CBD oil) is now legal… but as our new health care analyst Thomas Carroll pointed out, it’s still up to individual states to regulate these products. That explains why some states, like New York, are cracking down on edibles while other states allow these businesses to flourish.
CBD on its own, especially as CBD oil, provides milder health benefits without the mind-altering effects. Although there aren’t many clinical studies, there are a few that show CBD oil lowers anxiety. In fact, some folks in our office give their dogs CBD-infused treats to help them calm down. Researchers hypothesize CBD binds to serotonin receptors, which could explain the mechanism of action. They work similarly to drugs like BuSpar and Abilify, which work to boost the effects of traditional antidepressant drugs.
Similarly, CBD also reduces the number of seizures in children with a complicated epilepsy illness called Dravet syndrome. These are kids who experience many seizures that don’t respond to typical epilepsy drugs.
We’ve also seen some studies on CBD treating pain, high blood pressure, and even Parkinson’s. And as for THC, there’s a synthetic THC drug called Marinol. It’s legal and approved to treat nausea and appetite loss due to chemotherapy.
We’re going to follow the cannabis story both from a medical perspective and an investment opportunity. Our view right now is cautiously optimistic.
The reason is that we still want to see a lot more long-term and larger randomized trials. What’s more, although CBD seems safe and appears in so many products, it also carries with it some side effects like diarrhea, vomiting, and issues with liver function. So until those are addressed (likely with better formulations and more standardized dosages), we’d urge caution.
And remember, if you do go for a CBD latte or donut, don’t overdo it… mixing the oil with food or beverages can slow the absorption rate. That means you might not realize it’s kicking in and could take too much by accident.
But even with our caution, I am very excited for the new service we’re bringing to Stansberry Research. If anyone understands the nuances of the cannabis industry, it’s Thomas Carroll.
Thomas has spent years as a health care analyst and brings a new perspective on the boom he sees coming in cannabis investing. He thinks we might see a day soon where companies stop growing hemp and mass-produce the CBD in a laboratory environment. We’re just now at the forefront of this happening… and he has some great insight into how companies stand to profit from the new technology.
Don’t miss out this Wednesday when Thomas reveals why 2019 could be the year we see the cannabis industry begin to boom in earnest… and what worthy cannabis companies should rise to the top.
What We’re Reading…
- Something different: Is this the end of blockchain?
Here’s to our health, wealth, and a great retirement,
Dr. David Eifrig and the Health & Wealth Bulletin Research Team
March 25, 2019